The global DNA repair drugs market size was estimated to be USD 6.79 billion in 2023 and is expected to reach at USD 29.69 billion by 2034 with a CAGR of 14.35% during the forecast period 2024-2034. The rise in cancer rates, expanding efforts in research & development for new drugs & therapies, a surge in lifestyle modifications, heightened instances of alcohol and tobacco use, a growing demand for the creation of safe and efficacious cancer medications, the swift advancement of AI technology, increasing awareness about innovative treatment choices, and increase in the approval of DNA repair drug products are some of the key factors boosting the market growth.
Increasing in the approval of DNA repair drug products is predicted to boost the market growth during the forecast period. DNA repair medications are employed to fix damaged DNA and address cancer treatment needs. Genetic disorders can arise from DNA damage, but the human body possesses intrinsic mechanisms to rectify the DNA sequence. Drugs designed for DNA repair, including PARP inhibitors and other similar options, play a crucial role in treating diseases characterized by genetic aberrations. For instance, in September 2023, The Investigational New Drug (IND) Application for CT7439, a novel inhibitor targeting CDK12/13, has received approval from the FDA for the treatment of various advanced solid tumors.
By drug type, olaparib was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to the increasing incidence of diverse cancer types, a rising trend in adopting treatments for prostate cancer, and a surge in regulatory approvals for products. For instance, in March 2022, Lynparza (olaparib), jointly developed by AstraZeneca and MSD, has received approval in the United States for the adjuvant therapy of individuals with high-risk early breast cancer, characterized by germline BRCA mutations (gBRCAm) and HER2-negative status, who have undergone chemotherapy either prior to or following surgery. Additionally, PARP inhibitors is predicted to grow at the fastest CAGR during the forecast period owing to their efficacy lies in the precision of targeting distinct DNA repair mechanisms. PARP inhibitors are crafted to selectively act on a particular enzyme, Poly ADP-Ribose Polymerase (PARP), essential for DNA repair processes. By inhibiting PARP, cancer cells characterized by existing DNA repair deficiencies, such as those bearing BRCA mutations, become exceptionally susceptible to DNA damage.
By dosage form, tablets was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to a multiple manufacturers are providing effective tablets designed for DNA repair, leading to an increasing demand for these pills and a rise in the submission of marketing authorization applications to regulatory bodies. For instance, in April 2022, Janssen Pharmaceutical has applied to the European Medicines Agency (EMA) for marketing authorization for Niraparib in combination with abiraterone acetate. This combination is presented as a dual-action tablet (DAT) along with prednisolone, aiming for approval in the treatment of patients facing metastatic castration-resistant prostate cancer (mCRPC) after progression. Additionally, injectables is predicted to grow at the fastest CAGR during the forecast period owing to the escalating prevalence of cancer and the expanding efforts in research and development for innovative drugs and treatments.
By application, ovarian cancer was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to the increasing occurrence of ovarian cancer, accompanied by higher mortality rates and an evident lack of effective treatments, has created a demand for innovative therapeutic solutions. This demand, driven by the aspiration for improved survival rates, has spurred substantial research and development initiatives in the ovarian cancer domain. The progress in developing targeted treatments, notably PARP inhibitors, has demonstrated encouraging outcomes, positively influencing the growth of the DNA repair drugs industry. Additionally, peritoneal cancer is predicted to grow at the fastest CAGR during the forecast period owing to the escalating cases of peritoneal cancer, a rise in the need for therapeutic solutions for primary peritoneal cancer, an increasing demand for comprehensive treatment approaches within closed care settings, and a notable increase in approvals for marketing. For instance, in April 2023, The marketing authorization for AKEEGA (abiraterone acetate [AA] and niraparib), formulated as a dual-action tablet (DAT) alongside prednisone or prednisolone, has been granted by the European Commission. This approval, sanctioned by Janssen Pharmaceutical Companies of Johnson & Johnson, is specifically for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults with BRCA1/2 mutations (both somatic and germline) in cases where chemotherapy is not deemed clinically appropriate.
By distribution channel, retail pharmacies p was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to their extensive presence and accessibility, retail pharmacies offer convenient availability of prescription medications, over-the-counter drugs, and various healthcare essentials to the general public. The increasing approvals by regulatory bodies contribute to their role as a primary destination for individuals in search of medication and healthcare guidance. For instance, in January 2023, CLINUVEL's primary treatment, SCENESSE (afamelanotide 16mg), has received approval for commercial distribution in Europe, the USA, Israel, and Australia. It is recognized as the world's inaugural systemic photoprotective medication designed to prevent phototoxicity, including anaphylactoid reactions and burns, in adult patients diagnosed with erythropoietic protoporphyria (EPP). Additionally, hospital pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of chronic diseases, a rise in the volume of prescriptions from hospital pharmacies, and a growing preference among consumers.
North America region is anticipated for the highest revenue share during the forecast period owing to a heightened emphasis on engaging in research and development endeavors, increase in clinical trials related to genomic biomarkers, a growing prevalence of cancer, an escalating demand for viable treatment alternatives, and a rising level of corporate involvement in the development of drugs for cancer. For instance, in October 2022, Pfizer announced favorable top-line outcomes from the Phase 3 TALAPRO-2 trial evaluating TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, when administered in conjunction with XTANDI (enzalutamide) for men dealing with metastatic castration-resistant prostate cancer (mCRPC), irrespective of the presence or absence of homologous recombination repair (HRR) gene mutations. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the development of drugs focused on repairing DNA damage as part of the next generation of cancer treatments, rising number of investments in research related to DNA repair, an uptick in approvals by regulatory authorities, and surge in collaborations among various market players. For instance, in July 2023, KSQ Therapeutics has partnered with Roche through a license agreement to advance and market KSQ-4279. This novel compound is the first of its kind, serving as a powerful and specific small molecule inhibitor targeting USP1, a protein overseeing the DNA damage response.
Increasing in the approval of DNA repair drug products is predicted to boost the market growth during the forecast period. DNA repair medications are employed to fix damaged DNA and address cancer treatment needs. Genetic disorders can arise from DNA damage, but the human body possesses intrinsic mechanisms to rectify the DNA sequence. Drugs designed for DNA repair, including PARP inhibitors and other similar options, play a crucial role in treating diseases characterized by genetic aberrations. For instance, in September 2023, The Investigational New Drug (IND) Application for CT7439, a novel inhibitor targeting CDK12/13, has received approval from the FDA for the treatment of various advanced solid tumors.
By drug type, olaparib was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to the increasing incidence of diverse cancer types, a rising trend in adopting treatments for prostate cancer, and a surge in regulatory approvals for products. For instance, in March 2022, Lynparza (olaparib), jointly developed by AstraZeneca and MSD, has received approval in the United States for the adjuvant therapy of individuals with high-risk early breast cancer, characterized by germline BRCA mutations (gBRCAm) and HER2-negative status, who have undergone chemotherapy either prior to or following surgery. Additionally, PARP inhibitors is predicted to grow at the fastest CAGR during the forecast period owing to their efficacy lies in the precision of targeting distinct DNA repair mechanisms. PARP inhibitors are crafted to selectively act on a particular enzyme, Poly ADP-Ribose Polymerase (PARP), essential for DNA repair processes. By inhibiting PARP, cancer cells characterized by existing DNA repair deficiencies, such as those bearing BRCA mutations, become exceptionally susceptible to DNA damage.
By dosage form, tablets was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to a multiple manufacturers are providing effective tablets designed for DNA repair, leading to an increasing demand for these pills and a rise in the submission of marketing authorization applications to regulatory bodies. For instance, in April 2022, Janssen Pharmaceutical has applied to the European Medicines Agency (EMA) for marketing authorization for Niraparib in combination with abiraterone acetate. This combination is presented as a dual-action tablet (DAT) along with prednisolone, aiming for approval in the treatment of patients facing metastatic castration-resistant prostate cancer (mCRPC) after progression. Additionally, injectables is predicted to grow at the fastest CAGR during the forecast period owing to the escalating prevalence of cancer and the expanding efforts in research and development for innovative drugs and treatments.
By application, ovarian cancer was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to the increasing occurrence of ovarian cancer, accompanied by higher mortality rates and an evident lack of effective treatments, has created a demand for innovative therapeutic solutions. This demand, driven by the aspiration for improved survival rates, has spurred substantial research and development initiatives in the ovarian cancer domain. The progress in developing targeted treatments, notably PARP inhibitors, has demonstrated encouraging outcomes, positively influencing the growth of the DNA repair drugs industry. Additionally, peritoneal cancer is predicted to grow at the fastest CAGR during the forecast period owing to the escalating cases of peritoneal cancer, a rise in the need for therapeutic solutions for primary peritoneal cancer, an increasing demand for comprehensive treatment approaches within closed care settings, and a notable increase in approvals for marketing. For instance, in April 2023, The marketing authorization for AKEEGA (abiraterone acetate [AA] and niraparib), formulated as a dual-action tablet (DAT) alongside prednisone or prednisolone, has been granted by the European Commission. This approval, sanctioned by Janssen Pharmaceutical Companies of Johnson & Johnson, is specifically for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults with BRCA1/2 mutations (both somatic and germline) in cases where chemotherapy is not deemed clinically appropriate.
By distribution channel, retail pharmacies p was the highest revenue-grossing segment in the global DNA repair drugs market in 2023 owing to their extensive presence and accessibility, retail pharmacies offer convenient availability of prescription medications, over-the-counter drugs, and various healthcare essentials to the general public. The increasing approvals by regulatory bodies contribute to their role as a primary destination for individuals in search of medication and healthcare guidance. For instance, in January 2023, CLINUVEL's primary treatment, SCENESSE (afamelanotide 16mg), has received approval for commercial distribution in Europe, the USA, Israel, and Australia. It is recognized as the world's inaugural systemic photoprotective medication designed to prevent phototoxicity, including anaphylactoid reactions and burns, in adult patients diagnosed with erythropoietic protoporphyria (EPP). Additionally, hospital pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of chronic diseases, a rise in the volume of prescriptions from hospital pharmacies, and a growing preference among consumers.
North America region is anticipated for the highest revenue share during the forecast period owing to a heightened emphasis on engaging in research and development endeavors, increase in clinical trials related to genomic biomarkers, a growing prevalence of cancer, an escalating demand for viable treatment alternatives, and a rising level of corporate involvement in the development of drugs for cancer. For instance, in October 2022, Pfizer announced favorable top-line outcomes from the Phase 3 TALAPRO-2 trial evaluating TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, when administered in conjunction with XTANDI (enzalutamide) for men dealing with metastatic castration-resistant prostate cancer (mCRPC), irrespective of the presence or absence of homologous recombination repair (HRR) gene mutations. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the development of drugs focused on repairing DNA damage as part of the next generation of cancer treatments, rising number of investments in research related to DNA repair, an uptick in approvals by regulatory authorities, and surge in collaborations among various market players. For instance, in July 2023, KSQ Therapeutics has partnered with Roche through a license agreement to advance and market KSQ-4279. This novel compound is the first of its kind, serving as a powerful and specific small molecule inhibitor targeting USP1, a protein overseeing the DNA damage response.
Segmentation: DNA Repair Drugs Market Report 2023 - 2034
DNA Repair Drugs Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Niraparib
- Olaparib
- PARP Inhibitors
- Talazoparib
- Rucaparib
- Others
DNA Repair Drugs Market Analysis & Forecast by Dosage Form 2023 - 2034 (Revenue USD Bn)
- Capsules
- Injectables
- Tablets
DNA Repair Drugs Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Peritoneal Cancer
- Ovarian Cancer
- Breast Cancer
- Fallopian Tube Cancer
- Others
DNA Repair Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Others
DNA Repair Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. DNA Repair Drugs Market: Drug Type Estimates & Trend Analysis
8. DNA Repair Drugs Market: Dosage Form Estimates & Trend Analysis
9. DNA Repair Drugs Market: Application Estimates & Trend Analysis
10. DNA Repair Drugs Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America DNA Repair Drugs Market
13. Europe Global DNA Repair Drugs Market
14. Asia Pacific Global DNA Repair Drugs Market
15. Latin America Global DNA Repair Drugs Market
16. MEA Global DNA Repair Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Agilent Technologies
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Becton
- Dickinson and Company (BD)
- PerkinElmer Inc.
- Roche Diagnostics
- Illumina Inc.
- Fluidigm Corporation
- Dolomite Microfluidics
- Bio-Rad Laboratories Inc.
- RainDance Technologies (Bio-Rad)
- Cepheid (a Danaher company)
- Fluigent
- uFluidix
- Microfluidic ChipShop GmbH.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 6.79 Billion |
| Forecasted Market Value ( USD | $ 29.69 Billion |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
